Aging and osteoarthritis: the role of chondrocyte senescence and aging changes in the cartilage matrix  by Loeser, R.F.
Osteoarthritis and Cartilage (2009) 17, 971e979
ª 2009 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
doi:10.1016/j.joca.2009.03.002
International
Cartilage
Repair
SocietyReview
Aging and osteoarthritis: the role of chondrocyte senescence
and aging changes in the cartilage matrix
R. F. Loeser*
Section of Molecular Medicine, Department of Internal Medicine, Wake Forest University
School of Medicine, Winston-Salem, NC, USA
Summary
Objective: Age-related changes in multiple components of the musculoskeletal system may contribute to the well established link between
aging and osteoarthritis (OA). This review focused on potential mechanisms by which age-related changes in the articular cartilage could con-
tribute to the development of OA.
Methods: The peer-reviewed literature published prior to February 2009 in the PubMed database was searched using pre-deﬁned search cri-
teria. Articles, selected for their relevance to aging and articular chondrocytes or cartilage, were summarized.
Results: Articular chondrocytes exhibit an age-related decline in proliferative and synthetic capacity while maintaining the ability to produce
pro-inﬂammatory mediators and matrix degrading enzymes. These ﬁndings are characteristic of the senescent secretory phenotype and
are most likely a consequence of extrinsic stress-induced senescence driven by oxidative stress rather than intrinsic replicative senescence.
Extracellular matrix changes with aging also contribute to the propensity to develop OA and include the accumulation of proteins modiﬁed by
non-enzymatic glycation.
Conclusion: The effects of aging on chondrocytes and their matrix result in a tissue that is less able to maintain homeostasis when stressed,
resulting in breakdown and loss of the articular cartilage, a hallmark of OA. A better understanding of the basic mechanisms underlying se-
nescence and how the process may be modiﬁed could provide novel ways to slow the development of OA.
ª 2009 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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The prevalence of osteoarthritis (OA) rises directly with age
and it is the most common cause of chronic disability in
older adults1,2. However, it is important to note that OA is
not an inevitable consequence of aging; it is not a simple
‘‘wearing out’’ of the joints; and aging-related changes in
the joint can be distinguished from those due to disease.
Not all older adults develop OA and not all joints are equally
affected. Although the relationship between aging and the
development of OA is incompletely understood, it is becom-
ing apparent that aging changes in the musculoskeletal sys-
tem contribute to the development of OA by working in
conjunction with other factors such as obesity, joint injury,
and genetics. From studies of surgically induced OA in
young animals3, it is also apparent that OA-like changes
in the joint can develop without a signiﬁcant contribution
of aging. Thus aging and OA are inter-related but not
inter-dependent.
OA is best characterized as joint failure due to progres-
sive changes in several components of the musculoskeletal
system that include, but are not limited to, the articular*Address correspondence and reprint requests to: Richard F.
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971cartilage. Other joint structures, including the bone, muscle,
synovium, and soft tissues (ligaments, tendons, and in the
knee the menisci) are altered in OA but have not been as
extensively studied as the articular cartilage, especially in
regards to aging. This review focuses on how aging affects
the articular cartilage but many of the concepts discussed
will likely apply to other joint tissues as well.Methods
The PubMed database until February 1, 2009 was searched using the
search terms: aging, cell senescence, chondrocytes, cartilage, or OA. Arti-
cles, published in English, were selected for review based on their relevance
to the topic of aging changes in chondrocytes or cartilage that might contrib-
ute to the development of OA.ResultsCELL SENESCENCEThe term senescence is derived from the Latin word sen-
escere which means to grow old or to wane. Classical de-
scriptions of cell senescence most often refer to the loss
of the ability of mitotic cells to further divide in culture after
a period of 30e40 population doublings, often referred to as
the ‘‘Hayﬂick limit’’4. It could be argued that this form of
‘‘replicative senescence’’, resulting from an arrest in cell-
cycle progression, is an in vitro artifact of cell culture. How-
ever, in vivo relevance of replicative senescence, for at
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Fig. 1. Cell senescence. There are two major types of cell senes-
cence-replicative (intrinsic) and stress-induced (extrinsic). Senes-
cence is associated with telomere dysfunction, formation of SA
heterochromatin, and increased expression of p53, p21, and p16.
The senescent secretory phenotype is characterized by increased
production of cytokines, MMPs and growth factors such as EGF
or growth factor binding proteins such as IGFBP-7.
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that ﬁbroblasts isolated from older humans or animals reach
replicative senescence sooner than cells isolated from
younger individuals5. In addition, at least some of the
changes exhibited by cells that have undergone replicative
senescence can be found in cells in older adults, such as
the ﬁndings of shortened telomeres and the formation of
senescence-associated (SA) heterochromatin5.
Cell senescence may have evolved as a mechanism to
prevent cells with damaged DNA from being replicated
and thus to prevent tumor formation. Replicative senes-
cence is associated with changes in DNA structure and
function including a shortening in the telomeres accompa-
nied by telomere dysfunction6,7. Telomeres are found at
the ends of chromosomes and are incompletely replicated
during mitosis such that with each cell division a portion
of the end of the telomere is lost resulting in telomere short-
ening. The discovery of telomere shortening with each cell
division and the ﬁnding that a loss in telomere function
could cause cell-cycle arrest provided a mechanism for a
biological clock that over time would result in replicative
senescence.
However, cell senescence appears to be much more
complex than simple cell-cycle arrest occurring after a ﬁnite
number of cell divisions. Progressive telomere shorting due
to repeated cycles of cell division does not explain senes-
cence in post-mitotic cells such as neurons, or quiescent
cells such as chondrocytes. More recently, attention has
been drawn to other forms of cell senescence sometimes
referred to as ‘‘extrinsic’’ or ‘‘stress-induced’’ senescence
as opposed to the intrinsic senescence resulting from repli-
cation. Stress-induced senescence can occur from diverse
stimuli including ultraviolet radiation, oxidative damage, ac-
tivated oncogenes, and chronic inﬂammation7,8. Oxidative
damage to DNA can directly contribute to stress-induced
senescence and, because the ends of chromosomes are
particularly sensitive to oxidative damage, can result in telo-
mere shortening similar to that seen with replicative
senescence6,7.
Stress-induced senescence due to oxidative stress ﬁts
quite well with one of the long-standing theories of aging
ﬁrst proposed by Harman in the 1950s that invoked free
radicals, or reactive oxygen species (ROS), as mediators
of aging9. Oxidative stress has been found to induce cell se-
nescence in vitro and there is in vivo evidence for age-
related oxidative stress in many tissues5. As additional ev-
idence for a role of ROS in aging, increased expression of
the anti-oxidant enzyme catalase in mitochondria of trans-
genic mice can extend life-span and reduce age-related
changes in tissues such as the heart10,11. However, exten-
sion of life-span could not be reproduced in transgenic mice
overexpressing catalase in peroxisomes12, suggesting that
the source of ROS may be important in aging.
The concept that ROS contribute to cell senescence by
causing direct damage to proteins, lipids, and DNA is evolv-
ing to include the role of ROS in regulating cell signaling
pathways that promote senescence13. ROS are generated
by intracellular enzymes such as nicotinamide adenine di-
nucleotide phosphate (NADPH) oxidase and 5-lipoxyge-
nase in response to activation of speciﬁc cell signaling
pathways. These ROS serve as secondary messengers
that regulate signal transduction by activating redox-
sensitive kinases and inhibiting redox-sensitive phospha-
tases13,14. Insufﬁcient levels of ROS can be detrimental to
certain signaling pathways, such as the epidermal growth
factor (EGF) pathway that regulates cell proliferation, while
excessive levels of ROS may inhibit pathways, such as theinsulin signaling pathway, through activation of the stress-
induced kinase JNK13,15. A direct role for ROS in mediating
senescence has been demonstrated through a positive
feedback loop where mitogenic signaling that includes acti-
vation of protein kinase Cdelta (PKCd) by ROS cooperates
with the p16INK4A pathway to promote senescence16.
Senescent cells exhibit altered activity and expression of
regulatory proteins that control growth and proliferation
(Fig. 1). These include p53 and the cyclin-dependent kinase
inhibitors p21CIP1, and p16INK4A 5,8. Activation of p53 occurs
from DNA damage or from telomere shortening and serves
to inhibit cell-cycle progression. Activated p53 increases the
expression of p21 which contributes to senescence. As p21
declines in senescent cells, p16 is increased which appears
to serve a more long-term role in the inhibition of cell-cycle
progression through inhibition of retinoblastoma protein5.
The permanent state of cell-cycle arrest is also related to
epigenetic changes that include the formation of foci of het-
erochromatin referred to as senescence-associated hetero-
chromatin foci or SAHFs that include histone variants such
as the macro-H2A17. SAHFs and macro-H2A are used as
markers for senescent cells as are ﬁndings of increased
p16 expression17,18.
Senescent cells have also been found to have increased
levels of the lysosomal enzyme b-galactosidase that is de-
tectable at pH 6 rather than the normal pH 4.519. Detection
of b-galactosidase activity at pH 6 has been referred to as
senescence-associated (SA) b-galactosidase (SA-bgal).
Detection of activity at pH 6 is thought to be due to an in-
crease in lysosomal mass and is not speciﬁc to cell senes-
cence since it has been noted in immortalized cells, tumor
cell lines, and even in normal cells under certain cell culture
conditions5,19,20. We have noted positive staining for SA-b-
galactosidase in the immortalized chondrocyte cell line
C28I2 indicating it is not a speciﬁc marker for chondrocyte
senescence (unpublished observation).
In addition to causing cell-cycle arrest due to an increase
in expression of genes that inhibit proliferation, the changes
that occur in senescent cells can also result in the increased
production of cytokines, growth factors, and matrix
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as the senescent secretory phenotype8,18, this form of cell
senescence may be particularly relevant to the develop-
ment of OA. The senescent secretory phenotype is charac-
terized by the increased production of cytokines including
interleukin-6 (IL-6) and interleukin-1 (IL-1), MMPs, and
growth factors such as EGF. Recent studies have also pro-
vided evidence for a role of the IL-8 receptor chemokine XC
receptor2 (CXCR2)21 and insulin-like growth factor binding
protein-7 (IGFBP-7)22 in senescence, suggesting autocrine
loops of secreted proteins contribute to cell senescence.
The accumulation of cells expressing the senescent secre-
tory phenotype can also contribute to tissue aging through
damage to the extracellular matrix, such as seen with the
degradation of dermal collagen due to an age-related in-
crease in collagenase8,18.CHONDROCYTE SENESCENCEChondrocytes from older adults exhibit many of the
changes that are typical of cell senescence (Table I). Chon-
drocytes will divide in cell culture and after multiple pas-
sages will exhibit telomere shortening characteristic of
replicative senescence23. Evidence of telomere shortening
in chondrocytes has also been reported in cells isolated
from older adults24. But because adult articular chondro-
cytes rarely, if ever, divide in normal tissue in vivo25,26, it
would seem unlikely that they would experience telomere
shortening due to classical replicative senescence in vivo.
It is much more likely that chondrocyte senescence is the
extrinsic type induced by chronic stress. There is evidence
that telomere shortening noted in chondrocytes could be
due to DNA damage from ROS27,28. Interestingly, shorter
telomere length in peripheral leucocytes was associated
with radiographic hand OA in a cross-sectional study29.
This association might also suggest a link between sys-
temic oxidative stress, telomere erosion, and OA.
As discussed further below, an increase in chondrocyte
ROS levels can be aging-related30,31. However, ROS gen-
erated from excessive mechanical loading and/or stimula-
tion by cytokines could also contribute to DNA damage
and subsequent telomere shortening32,33. The lack of cell
division in normal adult articular cartilage and the lack of
a ready supply of local progenitor cells in cartilage suggest
that the chondrocytes present in the cartilage of an older
adult are likely to be the very same cells that were present
decades earlier. In contrast to many other tissues in the
body that experience a regular turnover of cells, the long
lifetime of chondrocytes would make these cells particularly
susceptible to the accumulation of changes from both aging
and extrinsic stress.
Evidence of cell senescence in tissues from older adults
can be obtained by examining for the presence of senes-
cence markers. These markers currently includeTable I
Features of chondrocyte senescence
Senescence feature References
Telomere shortening 23,24,27,28
[ SA-bgal, p53, p21, p16 24,35,36
[ Cytokine and MMP production 37,38,41e43
[ Oxidative stress/damage 30,31,35,75
Y Growth factor response 45e52
Y Growth factor production 53,54
[ Cell death 26,31,53,59e62,64histological staining for SA-bgal, SA heterochromatin, in-
creased p53, p21, and p16 and reduced Wnt218. Staining
for SA-bgal has been shown to be present in articular chon-
drocytes from older adults24 and in OA chondrocytes34.
Chondrocyte SA-bgal staining, as well as telomere shorten-
ing, has also been noted after treatment in vitro with IL-1b or
H2O2 consistent with stress-induced senescence
35. Stain-
ing for SA-bgal needs to be interpreted with caution since
this marker of cell senescence is not speciﬁc and can be
inﬂuenced by factors such as cell culture20. As noted above,
we have seen positive staining in immortalized cells that
would not be considered senescent.
Importantly, Dai et al 35. have provided evidence that
stress-induced senescence in vitro is also accompanied
by an increase in chondrocyte p53 and p21 expression as
additional markers of the senescent phenotype. The senes-
cence marker p16INK4A has also been examined and found
to be present at greater levels in OA chondrocytes relative
to age-matched normal tissue which in turn had higher
levels than fetal tissue36. In the latter study, siRNA knock-
down of p16INK4A was found to promote chondrocyte prolif-
eration and matrix gene expression consistent with a link
between senescence and the reduction in the ability of
chondrocytes to proliferate and repair the matrix.
There is mounting evidence that chondrocytes can ex-
hibit features of the senescent secretory phenotype which
has important implications for the role of chondrocyte se-
nescence in the development and progression of OA.
When compared to cells isolated from young tissue donors,
human articular chondrocytes from older adults were found
to secrete more MMP-13 into the media after stimulation
with either IL-1b or ﬁbronectin fragments37. Isolated human
chondrocytes were also found to produce more IL-137 and
more IL-738 with increasing donor age and, like IL-1 and ﬁ-
bronectin fragments, IL-7 can also induce MMP-13 produc-
tion38. MMP-13 serves as a major mediator of type II
collagen cleavage39,40. Studies have shown increased im-
munostaining for MMP-3 and MMP-13 in cartilage with ag-
ing41 as well as an age-related accumulation of collagen
neoepitopes representing denatured or cleaved colla-
gen42,43. Development of the senescent secretory pheno-
type also might explain the cross-sectional observation of
an increase in type II collagen degradation products in the
urine of healthy adults after about age 50 years44.
Another feature of chondrocyte senescence is a decline
in the proliferative and anabolic response of chondrocytes
to growth factor stimulation. An age-related loss in the nor-
mal mitogenic response to several different growth factors
has been noted including transforming growth factor-beta
(TGF-b), basic ﬁbroblast growth factor (bFGF), platelet-
derived growth factor (PDGF), insulin-like growth factor-I
(IGF-I), as well as those contained in fetal bovine serum45.
IGF-I is well known to stimulate cartilage matrix synthesis
and there is substantial evidence for an age-related decline
in the ability of IGF-I to stimulate proteoglycan and collagen
production46e48. TGF-b is another important cartilage ana-
bolic factor and studies in equine chondrocytes have noted
an age-related decline in response49. While the anabolic re-
sponse to TGF-b was maintained in cartilage from aging
mice, the ability of TGF-b to counteract the anti-anabolic af-
fects of IL-1 was lost50. The ability of bone morphogenic
protein-6 (BMP-6) to stimulate proteoglycan synthesis has
also been shown to decline with age in human chondro-
cytes51. Finally, a comparison of young and old bovine
chondrocytes revealed that the cells from older animals
produce less functional matrix when cultured with 10%
serum52.
Aging
Oxidative stress
Anabolic signaling
Catabolic signaling 
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Fig. 2. Theoretical model for the relationships of aging, oxidative
stress, and the development of OA. Aging-related oxidative stress
as well as abnormal biomechanical stress results in increased
levels of ROS in chondrocytes. The increase in ROS modulates an-
abolic and catabolic signaling pathways resulting in reduced matrix
synthesis, inhibition of growth factor expression, and increased
production of MMPs and cytokines that lead to matrix loss and
OA. Aging also results in increased formation of AGEs which
causes increased fatigue failure of the cartilage that when stressed
also contributes to the development of OA.
974 R. F. Loeser: Aging and osteoarthritisBesides a loss in the ability of chondrocytes to respond to
growth factor stimulation, there is also evidence for an age-
related reduction in the levels of certain growth factors in
cartilage. In the mouse, levels of TGF-b2 and TGF-b3 but
not TGF-b1 decline with age as does the level of the
TGF-b receptors I and II53. It has been shown that the ex-
pression and amount of osteogenic protein-1 (OP-1) (also
called BMP-7) present in human cartilage declines signiﬁ-
cantly with age54. The reduction in OP-1 levels may be
due to a recently discovered age-related increase in meth-
ylation of the chondrocyte OP-1 promoter55. DNA methyla-
tion and histone acetylation are two common epigenetic
mechanisms that serve to regulate the level of gene tran-
scription. The extent of DNA methylation in gene promoters
that are rich in CpG sequences (such as the OP-1 pro-
moter) can be altered with aging or in disease states and
result in altered gene expression56. In general, an increase
in promoter methylation will result in reduced gene
expression.
Thepotential for epigenetic regulation of chondrocyte gene
expression is just beginning to be explored. Although
changes in DNA methylation were not found to directly regu-
late aggrecan expression in normal aged or OA cartilage57,
inhibition of OP-1 promoter methylation in vitro resulted in
an increase in both IGF-I and aggrecan expression, most
likely from autocrine stimulation from an increase in OP-1 ex-
pression55. In contrast to the age-related increase in chon-
drocyte OP-1 promoter methylation, Roach et al58. found
that in OA chondrocytes there was a decrease in the methyl-
ation of promoter sites in several matrix degrading enzymes
including MMP-3, MMP-9, MMP-13, and a disintegrin and
metalloproteinasewith thrombospondinmotif-4 (ADAMTS-4)
that could explain their increased expression in OA. Most re-
cently, levels of the high-mobility group box (HMGB) protein
2, which is expressed in the superﬁcial zone of cartilage,
have been shown to decline with age in human and mouse
articular cartilage59. HMGB2 is a nonhistone chromatin pro-
tein that can serve as a transcriptional regulator. Taniguchi
et al 59. demonstrated that deletion of HMGB2 in transgenic
mice resulted in the early onset of OA-like changes in the su-
perﬁcial zone of cartilage that were associated with an in-
crease in susceptibility of chondrocytes to cell death.
Further studies on epigenetic regulation of chondrocyte
gene expressionmay provide novel insights into the changes
in chondrocyte gene expression noted in aging and OA.
Chondrocyte senescence can contribute to a decline in
chondrocyte numbers due to increased cell death, although
the extent of cell death with aging or in OA has varied
among studies60e62. In human hip cartilage, a 30% fall in
cell density between the ages of 30 and 70 years has
been reported63. In femoral head cartilage from rats,
a 46% decline in cell numbers was noted in old compared
to young adult rats31and an age-related increase in apopto-
tic chondrocytes in rat cartilage has been reported as well64.
In mice a similar age-related reduction in cell numbers in the
medial tibial cartilage was seen53. However, a study of
human knees found less than 5% cell loss with aging26.
There are certainly reasons to expect an age-related in-
crease in death of chondrocytes including the decline in
growth factor activity, the loss of survival promoting matrix
proteins, and the increase in oxidative damage. As noted
above, the response of chondrocytes to IGF-I declines
with age and IGF-I is an important autocrine survival factors
in cartilage65. Although matrix alterations occur with aging,
it is not known if these affect the ability of either type II col-
lagen66 or ﬁbronectin signaling through the a5b1 integrin67
to promote chondrocyte survival. Oxidative damage fromROS could also contribute to chondrocyte death. Levels
of ROS increase in cartilage with aging and chondrocytes
from older adults are more susceptible to ROS-mediated
cell death30. There is also evidence, at least in mouse car-
tilage, for an age-related decline in the anti-apoptotic protein
Bcl-2 and the Bcl-2 associated-athanogene-1 (Bag-1)68 that
could increase the susceptibility of chondrocytes to cell
death. Finally, the age-related decline in HMGB2, dis-
cussed above, may also make chondrocytes more suscep-
tible to cell death59. Because of a lack of replacement cells
in cartilage, any loss of cells due to cell death could have
important negative consequences.THE ROLE OF OXIDATIVE STRESS IN CHONDROCYTE
SENESCENCEOxidative stress may play a major role in the link between
aging and the development of OA (Fig. 2). Oxidative stress
results when the amount of ROS exceeds the anti-oxidant
capacity of the cell. This can be due to either increased pro-
duction of ROS or decreased levels of anti-oxidants and in
aging both are often responsible13. Glutathione is a major
intracellular anti-oxidant that also participates in regulating
redox signaling events. An increase in levels of oxidized
glutathione can be a sign of oxidative stress5. Evidence
for an age-related increase in oxidative stress in human
chondrocytes was obtained by ﬁnding an increase in the ra-
tio of oxidized to reduced glutathione in isolated cells30. In-
creased levels of intracellular ROS were also detected in
cartilage from old rats when compared to young adults31.
Importantly, age-related oxidative stress was found to
make human chondrocytes30 and rat chondrocytes31 more
susceptible to cell death mediated by oxidants. As addi-
tional evidence for oxidative stress playing a role in chon-
drocyte senescence, chondrocyte senescence in vitro was
associated with oxidative stress69 and exogenous addition
of ROS to cultured chondrocytes was found to induce
markers of the senescent phenotype35.
Table II
Aging changes in the cartilage matrix
Aging change References
[ AGE formation 97e101,103
Y Hydration 95
Y Aggrecan size 91e94
[ Collagen cleavage 42e44
[ Fatigue failure 90,95,100
Y Growth factor levels 53,54
[ Matrix calciﬁcation 108e111
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enzymes in cartilage with aging and in OA that would con-
tribute to chondrocyte oxidative stress. In chondrocytes
from aged rats, catalase, but not superoxide dismutase or
glutathione peroxidase, was found at lower levels than in
young adults31. Proteomic studies of human articular chon-
drocytes found a decrease in mitochondrial superoxide dis-
mutase with aging70 as well as a decrease in OA cells when
compared to cells from normal tissue71. Although not stud-
ied in aging, cartilage from adults with OA also had less
extracellular superoxide dismutase than normal cartilage72
and gene array studies performed with RNA isolated from
OA cells revealed a decreased expression of superoxide
dismutase and glutathione peroxidase73.
Increased levels ofROScancontribute to aging changes in
cells and tissues by causing oxidative damage to proteins,
lipids, and DNA. One marker of protein oxidation is the pres-
ence of nitrotyrosine which can be detected using anti-nitro-
tyrosine antibodies. Nitrotyrosine is created by the reaction
of protein tyrosine residues with peroxynitrite (ONOO)
formed when the ROS superoxide (O2
) and nitric oxide
(NO

) react74. Increased immunostaining for nitrotyrosine
has been noted with aging in normal human andmonkey car-
tilage75. Nitrotyrosine has also been detected in OA tis-
sue28,72,75. In monkey cartilage, the presence of positive
immunostaining for nitrotyrosine correlated with a reduced
anabolic response to IGF-I in chondrocytes isolated from
nearby tissue, suggesting that oxidative damage may be
one mechanism for the reduced growth factor response75.
In addition, excess levels of NO, a reactive nitrogen species,
have also been found to reduce the chondrocyte response to
IGF-I76. Likewise, earlier studies noted that treatment with
H2O2 inhibits chondrocyte proteoglycan synthesis
77.
The source of ROS contributing to oxidative stress and
oxidative damage can include both free radicals generated
as by-products of aerobic metabolism as well as ROS gen-
erated in response to speciﬁc stimuli such as growth factors
and cytokines. Although chondrocytes live in an environ-
ment with a low oxygen tension, they do consume oxygen
and therefore exhibit aerobic metabolism78. ROS have
been shown to be produced by chondrocytes in response
to stimulation by cytokines and growth factors, including
IL-1, TNF-a, FGF and TGF-b79e82 as well as by integrin
stimulation with ﬁbronectin fragments83. IL-1 stimulation of
ROS has been associated with chondrocyte DNA dam-
age33. Production of ROS by chondrocytes may also have
an important physiologic role in vivo. A recent study showed
that in the growth plate ROS regulate proliferation and the
initiation of hypertrophy84. The latter ﬁnding suggests a
potential connection between ROS production in articular
cartilage and chondrocyte hypertrophy observed in OA.
The underlying mechanisms by which oxidative stress
contributes to chondrocyte senescence have not been
well deﬁned. Studies in other cell types have provided evi-
dence that oxidative stress contributes to senescence
through modulation of the activity of speciﬁc cell signaling
pathways5,85. As noted above, this can be due to modula-
tion of the activity of a number of redox-sensitive kinases
and phosphatases. The activity of MAP kinase pathways,
which include ERK, JNK, and p38, may be particularly im-
portant. Caveolin-1 is an integral membrane protein that
serves as a scaffold and can regulate cell signaling path-
ways involved in senescence5. Caveolin-1 has been found
to play a role in chondrocyte senescence induced by IL-1
and H2O2 through activation of the p38 MAP kinase
35. We
have recent evidence that ROS can contribute to chondro-
cyte IGF-I resistance and reduced proteoglycan synthesisby causing an imbalance in the activity of the phosphoinosi-
tide-3 (PI-3) kinase-Akt pathway, which is necessary for
chondrocyte proteoglycan synthesis, and the mitogen-
activated protein kinase/extracellular regulated kinase
(MEK-ERK) MAP kinase pathway, which inhibits proteogly-
can synthesis (Yin et al., unpublished data). Because IGF-I
can also stimulate chondrocyte anti-oxidant capacity82,
resistance to IGF-I could further contribute to a redox
imbalance.
Oxidative stress may also contribute to chondrocyte se-
nescence by promoting endoplasmic reticulum (ER) stress.
ER stress has been shown to down-regulate expression of
cartilage matrix proteins including collagen type II and ag-
grecan and to increase chondrocyte apoptosis86,87.
Whether ER stress increases with age in cartilage has not
been determined. Further studies on redox regulation of
cell signaling in chondrocytes, as well as on ER stress,
should help to better deﬁne the mechanism of oxidative
stress-induced chondrocyte senescence and may provide
new targets for slowing the aging process in cartilage.AGING IN THE CARTILAGE MATRIXAge-related changes in the cartilage matrix have been re-
ported that could be important in contributing to the develop-
ment of OA (Table II). There is evidence from magnetic
resonance imaging (MRI) studies that the articular cartilage
in the knee thins with aging, particularly at the femoral side
of the joint88 and at the patella89. Cartilage thinning is consis-
tent with a gradual loss of cartilage matrix with aging as well
as a decrease in cartilage hydration and cellularity. A recent
study of human femoral cartilage demonstrated an age-re-
lated decrease in cellularity and glycosaminoglycan content
that could contribute to weakening of the tissue90. Age-re-
lated changes in the size, structure, and sulfation pattern of
aggrecan have also been reported91e94. Aggrecan’s abun-
dant negatively charged sulfates, which are very hydrophilic,
are responsible for maintaining the high content (about
70e80%) of water in cartilage. Aging changes in aggrecan
likely contribute to a loss in cartilage resiliency and hydra-
tion95. There is also evidence for an age-related accumula-
tion of aggrecan fragments containing the hyaluronic acid
binding region96. The aggrecan fragments that remain bound
to hyaluronic acid can occupy the space where a newly syn-
thesized complete aggrecan molecule would normally bind
and thus result in smaller proteoglycan aggregates being
present with increasing age91.
The aging cartilage matrix appears to be particularly sus-
ceptible to the accumulation of advanced glycation end-
products (AGEs). AGEs are formed by reducing sugars
such as glucose, fructose or ribose, reacting with lysine or
arginine residues in a process of non-enzymatic glycation97.
The low turnover rate of type II collagen, calculated to be
over 100 years98, allows for the accumulation of AGEs
that have been noted in human knee tissue97,99. AGE
976 R. F. Loeser: Aging and osteoarthritisformation in collagen can result in increased cross-linking.
The most common AGE-related cross-link is pentosidine
which has been found to be present in cartilage in increas-
ing amounts with age98,100,101. Formation of excessive col-
lagen cross-links affects the biomechanical properties of
cartilage resulting in increased stiffness making the carti-
lage more brittle102 and increasing the susceptibility of the
tissue to fatigue failure100.
In addition to altering the biomechanical properties of car-
tilage, increased levels of AGEs in cartilage may also affect
chondrocyte function. An association has been noted be-
tween AGE formation and a decline in chondrocyte anabolic
activity103. The mechanism by which AGEs affect chondro-
cyte function may include a direct interaction with cell recep-
tors such as RAGE (the Receptor for Advanced Glycation
End-products). RAGE is expressed by chondrocytes and
RAGE levels in cartilage increase with both aging and the
development of OA104. Stimulation of chondrocyte RAGE
by AGE-albumin, produced in vitro105, or by S100 proteins,
which can also bind RAGE and are present in
vivo104,106,107, results in increased production of MMPs as
well as a modulation of the chondrocyte phenotype to hy-
pertrophy. Because increases in MMP production and
chondrocyte hypertrophy are hallmarks of OA, signaling
through RAGE could play an important role in connecting
age-related changes in the matrix to the development of
OA. Chondrocyte RAGE signaling requires ROS107, provid-
ing another link between oxidative stress, aging, and OA.
Despite the fact that type II collagen has a very long half-
life in cartilage, there is evidence for an age-related in-
crease in collagen turnover. Type II collagen degradation
was noted to increase with age in macroscopically normal
ankle cartilage43. In that study, the ratio of cleaved/dena-
tured type II collagen was examined and revealed a highly
signiﬁcant positive correlation with age (r¼ 0.78,
P< 0.0001) suggesting a disassociation between cleavage
and denaturation with aging. An increase in cleavage with-
out a similar level of denaturation could be due to the age-
related increase in collagen cross-linking from AGEs.
An age-related increase in calciﬁcation of the articular
cartilage, and the menisci in the knee, has been demon-
strated radiographically108,109. This may be related to an in-
crease in the activity of transglutaminase, an enzyme
involved in the biomineralization process110 and to an in-
crease in inorganic pyrophosphate production in response
to transforming growth factor-b stimulation111. Despite
a strong association among age, chondrocalcinosis, and
the presence of OA108,109, the precise role of cartilage ma-
trix calciﬁcation in the development of OA is not clear, in
part due to the number of older people with asymptomatic
chondrocalcinosis112.AGING AND THE LOSS OF HOMEOSTASISIf aging does not directly cause OA, how does it contrib-
ute to the development and/or progression of the disease?
It is now fairly well accepted that in OA, at least in the artic-
ular cartilage, an imbalance exists in anabolic and catabolic
pathways that favors matrix degradation113e115. We have
proposed116, that aging changes including excessive levels
of ROS could play an important role in tipping the balance of
anabolic and catabolic signaling (Fig. 2). An alteration in the
level of anabolic and catabolic activity represents a loss in
homeostasis. Many of the chronic degenerative conditions
associated with aging appear to result from an age-related
loss in the ability of cells and tissues in the body to maintain
homeostasis, particularly when put under stress117.The obvious stress for joint tissues is the mechanical
stress that results from joint loading and motion. It is clear
that excessive or abnormal mechanical stresses play a cen-
tral role in the development of OA118. Under conditions
where an anatomically normal joint is stressed, healthy joint
tissues appear to be very capable of adapting to stress. As
an example of successful adaptation, the chronic repetitive
loads endured by long distance runners do not appear to
result in OA later in life119,120. The development of OA
occurs in joints that are unable to maintain homeostasis.
Excessive loads, particularly when placed on a malaligned
joint, overwhelm the homeostatic mechanisms leading to
OA118,121,122.
OA is rare in young adults and even serious joint injuries
usually don’t manifest as OA until years later, suggesting
that young joint tissues can compensate, to some degree,
to abnormal mechanical stress. But with aging, the ability to
compensate and maintain homeostasis declines. Older
adults who experience a joint injury develop OA much more
rapidly than younger adults with a similar injury123. Likewise,
older adultswhodevelop inﬂammatory arthritis, suchas rheu-
matoid arthritis, exhibit more rapid joint destruction relative to
younger adults124. The age-related changes in the chondro-
cyte and in the cartilagematrix describedabove likely result in
a tissue that cannot adequately maintain homeostasis when
stressed resulting in matrix destruction and loss.
Conclusions
As we learn more about the basic biology of aging and
how aging affects joint tissues such as the articular carti-
lage, the links between aging and the development of OA
are becoming more apparent. It is unlikely that OA is a direct
consequence of aging joints but rather aging affects the
ability of the articular cartilage, and likely other joint tissues
as well, to maintain homeostasis when stressed. The aging
chondrocyte’s ability to produce and repair the extracellular
matrix is compromised due to a decline in growth factor
activity. This appears to be related to both a decline in the
local availability of growth factors, including BMP-7 and
TGF-b, as well as a decline in the chondrocyte’s response
to stimulation with growth factors such as IGF-I. The latter
ﬁndings suggest that growth factor therapy, being devel-
oped as a way to stimulate cartilage matrix production
and repair, may not work well in older adults.
Chondrocyte senescence is associated with an increased
production of inﬂammatory mediators and matrix degrading
enzymes characteristic of the senescent secretory pheno-
type. The aging cartilage matrix likely contributes to these
changes in chondrocyte function and also contributes to
a loss in homeostasis due to altered biomechanical proper-
ties. Age-related oxidative stress and damage may play
a central role in cartilage aging through modulation of cell
signaling pathways that regulate anabolic and catabolic ac-
tivity. Although the use of general anti-oxidants as therapies
for aging-related diseases has not met with much success
to date, it is possible that modulating the activity of a speciﬁc
set of redox-regulated pathways may be more efﬁcacious.
Further studies aimed at elucidating the mechanisms that
contribute to chondrocyte and cartilage aging should un-
cover new ways to slow the aging process in joint tissues
and postpone the development of OA.Conﬂict of interest
None declared.
977Osteoarthritis and Cartilage Vol. 17, No. 8Acknowledgments
Dr Loeser’s work was supported by the National Institute on
Aging (RO1 AG16697 and the Wake Forest University
Claude D. Pepper Older Americans Independence Center
P30 AG021332), the National Institute on Arthritis, Musculo-
skeletal and Skin Diseases (RO1 AR49003), the American
Federation for Aging Research, and the Dorothy Rhyne
Kimbrell and Willard Duke Kimbrell Professorship.References
1. Prevalence of disabilities and associated health conditions among
adults e United States, 1999. MMWR Morb Mortal Wkly Rep 2001;
50:120e5.
2. DillonCF,RaschEK,GuQ,HirschR.Prevalence of kneeosteoarthritis in
the United States: arthritis data from the Third National Health and Nu-
trition Examination Survey 1991e94. J Rheumatol 2006;33:2271e9.
3. Glasson SS, Blanchet TJ, Morris EA. The surgical destabilization of the
medial meniscus (DMM) model of osteoarthritis in the 129/SvEv
mouse. Osteoarthritis Cartilage 2007;15:1061e9.
4. Hayﬂick L. Intracellular determinants of cell aging. Mech Ageing Dev
1984;28:177e85.
5. Muller M. Cellular senescence: molecular mechanisms, in vivo signiﬁ-
cance, and redox considerations. AntioxidRedoxSignal 2009;11:59e98.
6. Goyns MH. Genes, telomeres and mammalian ageing. Mech Ageing
Dev 2002;123:791e9.
7. Itahana K, Campisi J, Dimri GP. Mechanisms of cellular senescence in
human and mouse cells. Biogerontology 2004;5:1e10.
8. Campisi J. Senescent cells, tumor suppression, and organismal aging:
good citizens, bad neighbors. Cell 2005;120:513e22.
9. Harman D. Aging: a theory based on free radical and radiation chem-
istry. J Gerontol 1956;11:298e300.
10. Schriner SE, Linford NJ, Martin GM, Treuting P, Ogburn CE, Emond M,
et al. Extension of murine life span by overexpression of catalase tar-
geted to mitochondria. Science 2005;308:1909e11.
11. Treuting PM, Linford NJ, Knoblaugh SE, Emond MJ, Morton JF,
Martin GM, et al. Reduction of age-associated pathology in old mice
by overexpression of catalase in mitochondria. J Gerontol A Biol Sci
Med Sci 2008;63:813e22.
12. Perez VI, Van Remmen H, Bokov A, Epstein CJ, Vijg J, Richardson A.
The overexpression of major antioxidant enzymes does not extend
the lifespan of mice. Aging Cell 2008.
13. Finkel T, Holbrook NJ. Oxidants, oxidative stress and the biology of
ageing. Nature 2000;408:239e47.
14. Kamata H, Hirata H. Redox regulation of cellular signalling. Cell Signal
1999;11:1e14.
15. Nishikawa T, Kukidome D, Sonoda K, Fujisawa K, Matsuhisa T,
Motoshima H, et al. Impact of mitochondrial ROS production in the
pathogenesis of insulin resistance. Diabetes Res Clin Pract 2007;
77(Suppl 1):S161e4.
16. Takahashi A, Ohtani N, Yamakoshi K, Iida S, Tahara H, Nakayama K,
et al. Mitogenic signalling and the p16INK4a-Rb pathway cooperate to
enforce irreversible cellular senescence. Nat Cell Biol 2006;8:
1291e7.
17. Zhang R, Adams PD. Heterochromatin and its relationship to cell se-
nescence and cancer therapy. Cell Cycle 2007;6:784e9.
18. Campisi J, d’Adda di Fagagna F. Cellular senescence: when bad
things happen to good cells. Nat Rev Mol Cell Biol 2007;8:729e40.
19. Itahana K, Campisi J, Dimri GP. Methods to detect biomarkers of cel-
lular senescence: the senescence-associated beta-galactosidase as-
say. Methods Mol Biol 2007;371:21e31.
20. Severino J, Allen RG, Balin S, Balin A, Cristofalo VJ. Is beta-galactosi-
dase staining a marker of senescence in vitro and in vivo? Exp Cell
Res 2000;257:162e71.
21. Acosta JC, O’Loghlen A, Banito A, Guijarro MV, Augert A, Raguz S,
et al. Chemokine signaling via the CXCR2 receptor reinforces senes-
cence. Cell 2008;133:1006e18.
22. Wajapeyee N, Serra RW, Zhu X, Mahalingam M, Green MR. Onco-
genic BRAF induces senescence and apoptosis through pathways
mediated by the secreted protein IGFBP7. Cell 2008;132:363e74.
23. Parsch D, Brummendorf TH, Richter W, Fellenberg J. Replicative aging
of human articular chondrocytes during ex vivo expansion. Arthritis
Rheum 2002;46:2911e6.
24. Martin JA, Buckwalter JA. Telomere erosion and senescence in human
articular cartilage chondrocytes. J Gerontol A Biol Sci Med Sci 2001;
56:B172e9.
25. Mankin HJ. Localization of tritiated thymidine in articular cartilage of
rabbits. J Bone Joint Surg 1963;45-A:529e40.
26. Aigner T, Hemmel M, Neureiter D, Gebhard PM, Zeiler G, Kirchner T,
et al. Apoptotic cell death is not a widespread phenomenon in normalaging and osteoarthritis human articular knee cartilage: a study of pro-
liferation, programmed cell death (apoptosis), and viability of chondro-
cytes in normal and osteoarthritic human knee cartilage. Arthritis
Rheum 2001;44:1304e12.
27. Martin JA, Klingelhutz AJ, Moussavi-Harami F, Buckwalter JA. Effects
of oxidative damage and telomerase activity on human articular carti-
lage chondrocyte senescence. J Gerontol A Biol Sci Med Sci 2004;59:
324e37.
28. Yudoh K, Nguyen T, Nakamura H, Hongo-Masuko K, Kato T,
Nishioka K. Potential involvement of oxidative stress in cartilage se-
nescence and development of osteoarthritis: oxidative stress induces
chondrocyte telomere instability and downregulation of chondrocyte
function. Arthritis Res Ther 2005;7:R380e91.
29. Zhai G, Aviv A, Hunter DJ, Hart DJ, Gardner JP, Kimura M, et al.
Reduction of leucocyte telomere length in radiographic hand osteo-
arthritis: a population-based study. Ann Rheum Dis 2006;65:
1444e8.
30. Del Carlo Jr M, Loeser RF. Increased oxidative stress with aging re-
duces chondrocyte survival: Correlation with intracellular glutathione
levels. Arthritis Rheum 2003;48:3419e30.
31. Jallali N, Ridha H, Thrasivoulou C, Underwood C, Butler PE, Cowen T.
Vulnerability to ROS-induced cell death in ageing articular cartilage:
the role of antioxidant enzyme activity. Osteoarthritis Cartilage 2005;
13:614e22.
32. Kurz B, Lemke AK, Fay J, Pufe T, Grodzinsky AJ, Schunke M. Patho-
mechanisms of cartilage destruction by mechanical injury. Ann Anat
2005;187:473e85.
33. Davies CM, Guilak F, Weinberg JB, Fermor B. Reactive nitrogen and
oxygen species in interleukin-1-mediated DNA damage associated
with osteoarthritis. Osteoarthritis Cartilage 2008;16:624e30.
34. Price JS, Waters JG, Darrah C, Pennington C, Edwards DR,
Donell ST, et al. The role of chondrocyte senescence in osteoarthritis.
Aging Cell 2002;1:57e65.
35. Dai SM, Shan ZZ, Nakamura H, Masuko-Hongo K, Kato T, Nishioka K,
et al. Catabolic stress induces features of chondrocyte senescence
through overexpression of caveolin 1: possible involvement of caveo-
lin 1-induced down-regulation of articular chondrocytes in the patho-
genesis of osteoarthritis. Arthritis Rheum 2006;54:818e31.
36. Zhou HW, Lou SQ, Zhang K. Recovery of function in osteoarthritic
chondrocytes induced by p16INK4a-speciﬁc siRNA in vitro. Rheuma-
tology (Oxford) 2004;43:555e68.
37. Forsyth CB, Cole A, Murphy G, Bienias JL, Im HJ, Loeser Jr RF. In-
creased matrix metalloproteinase-13 production with aging by human
articular chondrocytes in response to catabolic stimuli. J Gerontol A
Biol Sci Med Sci 2005;60:1118e24.
38. Long D, Blake S, Song XY, Lark M, Loeser RF. Human articular chon-
drocytes produce IL-7 and respond to IL-7 with increased production
of matrix metalloproteinase-13. Arthritis Res Ther 2008;10:R23.
39. Mitchell PG, Magna HA, Reeves LM, Lopresti-Morrow LL, Yocum SA,
Rosner PJ, et al. Cloning, expression, and type II collagenolytic activ-
ity of matrix metalloproteinase-13 from human osteoarthritic cartilage.
J Clin Invest 1996;97:761e8.
40. Billinghurst RC, Dahlberg L, Ionescu M, Reiner A, Bourne R,
Rorabeck C, et al. Enhanced cleavage of type II collagen by collage-
nases in osteoarthritic articular cartilage. J Clin Invest 1997;99:
1534e45.
41. Wu W, Billinghurst RC, Pidoux I, Antoniou J, Zukor D, Tanzer M, et al.
Sites of collagenase cleavage and denaturation of type II collagen in
aging and osteoarthritic articular cartilage and their relationship to the
distribution of matrix metalloproteinase 1 and matrix metalloprotei-
nase 13. Arthritis Rheum 2002;46:2087e94.
42. Hollander AP, Pidoux I, Reiner A, Rorabeck C, Bourne R, Poole AR.
Damage to type II collagen in aging and osteoarthritis starts at the ar-
ticular surface, originates around chondrocytes, and extends into the
cartilage with progressive degeneration. J Clin Invest 1995;96:
2859e69.
43. Aurich M, Poole AR, Reiner A, Mollenhauer C, Margulis A,
Kuettner KE, et al. Matrix homeostasis in aging normal human ankle
cartilage. Arthritis Rheum 2002;46:2903e10.
44. Mouritzen U, Christgau S, Lehmann HJ, Tanko LB, Christiansen C.
Cartilage turnover assessed with a newly developed assay measuring
collagen type II degradation products: inﬂuence of age, sex, meno-
pause, hormone replacement therapy, and body mass index. Ann
Rheum Dis 2003;62:332e6.
45. Guerne PA, Blanco F, Kaelin A, Desgeorges A, Lotz M. Growth factor
responsiveness of human articular chondrocytes in aging and devel-
opment. Arthritis Rheum 1995;38:960e8.
46. Martin JA, Ellerbroek SM, Buckwalter JA. Age-related decline in chon-
drocyte response to insulin-like growth factor-I: the role of growth fac-
tor binding proteins. J Orthop Res 1997;15:491e8.
47. Loeser RF, Shanker G, Carlson CS, Gardin JF, Shelton BJ,
Sonntag WE. Reduction in the chondrocyte response to insulin-like
growth factor 1 in aging and osteoarthritis: studies in a non-human
978 R. F. Loeser: Aging and osteoarthritisprimate model of naturally occurring disease. Arthritis Rheum 2000;
43:2110e20.
48. Messai H, Duchossoy Y, Khatib A, Panasyuk A, Mitrovic DR. Articular
chondrocytes from aging rats respond poorly to insulin-like growth fac-
tor-1: an altered signaling pathway. Mech Ageing Dev 2000;115:
21e37.
49. Iqbal J, Dudhia J, Bird JL, Bayliss MT. Age-related effects of TGF-beta
on proteoglycan synthesis in equine articular cartilage. Biochem Bio-
phys Res Commun 2000;274:467e71.
50. Scharstuhl A, van Beuningen HM, Vitters EL, van der Kraan PM, van
den Berg WB. Loss of transforming growth factor counteraction on in-
terleukin 1 mediated effects in cartilage of old mice. Ann Rheum Dis
2002;61:1095e8.
51. Bobacz K, Gruber R, Soleiman A, Erlacher L, Smolen JS,
Graninger WB. Expression of bone morphogenetic protein 6 in healthy
and osteoarthritic human articular chondrocytes and stimulation of
matrix synthesis in vitro. Arthritis Rheum 2003;48:2501e8.
52. Tran-Khanh N, Hoemann CD, McKee MD, Henderson JE,
Buschmann MD. Aged bovine chondrocytes display a diminished ca-
pacity to produce a collagen-rich, mechanically functional cartilage ex-
tracellular matrix. J Orthop Res 2005;23:1354e62.
53. Blaney Davidson EN, Scharstuhl A, Vitters EL, van der Kraan PM, van
den Berg WB. Reduced transforming growth factor-beta signaling in
cartilage of old mice: role in impaired repair capacity. Arthritis Res
Ther 2005;7:R1338e47.
54. Chubinskaya S, Kumar B, Merrihew C, Heretis K, Rueger DC,
Kuettner KE. Age-related changes in cartilage endogenous osteo-
genic protein-1 (OP-1). Biochim Biophys Acta 2002;1588:126e34.
55. Loeser RF, Im HJ, Richardson B, Lu Q, Chubinskaya S. Methylation of
the OP-1 promoter: potential role in the age-related decline in OP-1
expression in cartilage. Osteoarthritis Cartilage 2009;17:513e7.
56. Richardson B. Impact of aging on DNA methylation. Ageing Res Rev
2003;2:245e61.
57. Poschl E, Fidler A, Schmidt B, Kallipolitou A, Schmid E, Aigner T. DNA
methylation is not likely to be responsible for aggrecan down regula-
tion in aged or osteoarthritic cartilage. Ann Rheum Dis 2005;64:
477e80.
58. Roach HI, Yamada N, Cheung KS, Tilley S, Clarke NM, Oreffo RO,
et al. Association between the abnormal expression of matrix-degrad-
ing enzymes by human osteoarthritic chondrocytes and demethylation
of speciﬁc CpG sites in the promoter regions. Arthritis Rheum 2005;
52:3110e24.
59. Taniguchi N, Carames B, Ronfani L, Ulmer U, Komiya S, Bianchi ME,
et al. Aging-related loss of the chromatin protein HMGB2 in articular
cartilage is linked to reduced cellularity and osteoarthritis. Proc Natl
Acad Sci U S A 2009;106:1181e6.
60. Horton Jr WE, Feng L, Adams C. Chondrocyte apoptosis in develop-
ment, aging and disease. Matrix Biol 1998;17:107e15.
61. Aigner T, Kim HA, Roach HI. Apoptosis in osteoarthritis. Rheum Dis
Clin North Am 2004;30:639e53, xi.
62. Kuhn K, D’Lima DD, Hashimoto S, Lotz M. Cell death in cartilage.
Osteoarthritis Cartilage 2004;12:1e16.
63. Vignon E, Arlot M, Patricot LM, Vignon G. The cell density of human
femoral head cartilage. Clin Orthop 1976;121:303e8.
64. Adams CS, Horton Jr WE. Chondrocyte apoptosis increases with age
in the articular cartilage of adult animals. Anat Rec 1998;250:418e25.
65. Loeser RF, Shanker G. Autocrine stimulation by insulin-like growth fac-
tor 1 and insulin-like growth factor 2 mediates chondrocyte survival in
vitro. Arthritis Rheum 2000;43:1552e9.
66. Yang C, Li SW, Helminen HJ, Khillan JS, Bao Y, Prockop DJ. Apopto-
sis of chondrocytes in transgenic mice lacking collagen II. Exp Cell
Res 1997;235:370e3.
67. Pulai JI, Del Carlo Jr M, Loeser RF. The alpha5beta1 integrin provides
matrix survival signals for normal and osteoarthritic human articular
chondrocytes in vitro. Arthritis Rheum 2002;46:1528e35.
68. Kinkel MD, Yagi R, McBurney D, Nugent A, Horton Jr WE. Age-related
expression patterns of Bag-1 and Bcl-2 in growth plate and articular
chondrocytes. Anat Rec A Discov Mol Cell Evol Biol 2004;279:720e8.
69. Pfeuty A, Gueride M. Peroxide accumulation without major mitochon-
drial alteration in replicative senescence. FEBS Lett 2000;468:43e7.
70. Ruiz-Romero C, Lopez-Armada MJ, Blanco FJ. Mitochondrial proteo-
mic characterization of human normal articular chondrocytes. Osteo-
arthritis Cartilage 2006;14:507e18.
71. Ruiz-Romero C, Calamia V, Mateos J, Carreira V, Martinez-Gomariz M,
FernandezM, et al. Mitochondrial dysregulation of osteoarthritic human
articular chondrocytes analyzed by proteomics: a decrease in mito-
chondrial superoxide dismutase points to a redox imbalance. Mol Cell
Proteomics 2008.
72. Regan E, Flannelly J, Bowler R, Tran K, Nicks M, Carbone BD, et al.
Extracellular superoxide dismutase and oxidant damage in osteoar-
thritis. Arthritis Rheum 2005;52:3479e91.
73. Aigner T, Fundel K, Saas J, Gebhard PM, Haag J, Weiss T, et al.
Large-scale gene expression proﬁling reveals major pathogeneticpathways of cartilage degeneration in osteoarthritis. Arthritis Rheum
2006;54:3533e44.
74. Reiter CD, Teng RJ, Beckman JS. Superoxide reacts with nitric oxide
to nitrate tyrosine at physiological pH via peroxynitrite. J Biol Chem
2000;275:32460e6.
75. Loeser RF, Carlson CS, Carlo MD, Cole A. Detection of nitrotyrosine in
aging and osteoarthritic cartilage: correlation of oxidative damage with
the presence of interleukin-1beta and with chondrocyte resistance to
insulin-like growth factor 1. Arthritis Rheum 2002;46:2349e57.
76. Studer RK, Levicoff E, Georgescu H, Miller L, Jaffurs D, Evans CH. Ni-
tric oxide inhibits chondrocyte response to IGF-I: inhibition of IGF-IR-
beta tyrosine phosphorylation. Am J Physiol Cell Physiol 2000;279:
C961e9.
77. Baker MS, Feigan J, Lowther DA. Chondrocyte antioxidant defences:
the roles of catalase and glutathione peroxidase in protection against
H2O2 dependent inhibition of proteoglycan biosynthesis. J Rheumatol
1988;15:670e7.
78. Zhou S, Cui Z, Urban JP. Factors inﬂuencing the oxygen concentration
gradient from the synovial surface of articular cartilage to the cartilage-
bone interface: a modeling study. Arthritis Rheum 2004;50:3915e24.
79. Rathakrishnan C, Tiku K, Raghavan A, Tiku ML. Release of oxygen
radicals by articular chondrocytes: a study of luminol-dependent
chemiluminescence and hydrogen peroxide secretion. J Bone Miner
Res 1992;7:1139e48.
80. Lo YY, Cruz TF. Involvement of reactive oxygen species in cytokine
and growth factor induction of c-fos expression in chondrocytes.
J Biol Chem 1995;270:11727e30.
81. Lo YY, Conquer JA, Grinstein S, Cruz TF. Interleukin-1 beta induction of
c-fos and collagenase expression in articular chondrocytes: involve-
ment of reactive oxygen species. J Cell Biochem 1998;69:19e29.
82. Jallali N, Ridha H, Thrasivoulou C, Butler P, Cowen T. Modulation of
intracellular reactive oxygen species level in chondrocytes by IGF-1,
FGF, and TGF-beta1. Connect Tissue Res 2007;48:149e58.
83. Del Carlo M, Schwartz D, Erickson EA, Loeser RF. Endogenous pro-
duction of reactive oxygen species is required for stimulation of hu-
man articular chondrocyte matrix metalloproteinase production by
ﬁbronectin fragments. Free Radic Biol Med 2007;42:1350e8.
84. Morita K, Miyamoto T, Fujita N, Kubota Y, Ito K, Takubo K, et al. Re-
active oxygen species induce chondrocyte hypertrophy in endochon-
dral ossiﬁcation. J Exp Med 2007;204:1613e23.
85. Finkel T. Oxidant signals and oxidative stress. Curr Opin Cell Biol
2003;15:247e54.
86. Yang L, Carlson SG, McBurney D, Horton Jr WE. Multiple signals in-
duce endoplasmic reticulum stress in both primary and immortalized
chondrocytes resulting in loss of differentiation, impaired cell growth,
and apoptosis. J Biol Chem 2005;280:31156e65.
87. Yang L, McBurney D, Tang SC, Carlson SG, Horton Jr WE. A novel
role for Bcl-2 associated-athanogene-1 (Bag-1) in regulation of the
endoplasmic reticulum stress response in mammalian chondrocytes.
J Cell Biochem 2007;102:786e800.
88. Hudelmaier M, Glaser C, Hohe J, Englmeier KH, Reiser M, Putz R,
et al. Age-related changes in the morphology and deformational be-
havior of knee joint cartilage. Arthritis Rheum 2001;44:2556e61.
89. Ding C, Cicuttini F, Scott F, Cooley H, Jones G. Association between
age and knee structural change: a cross sectional MRI based study.
Ann Rheum Dis 2005;64:549e55.
90. Temple MM, Bae WC, Chen MQ, Lotz M, Amiel D, Coutts RD, et al.
Age- and site-associated biomechanical weakening of human articu-
lar cartilage of the femoral condyle. Osteoarthritis Cartilage 2007;15:
1042e52.
91. Buckwalter JA, Roughley PJ, Rosenberg LC. Age-related changes in
cartilage proteoglycans: quantitative electron microscopic studies. Mi-
crosc Res Tech 1994;28:398e408.
92. Dudhia J, Davidson CM, Wells TM, Vynios DH, Hardingham TE,
Bayliss MT. Age-related changes in the content of the C-terminal re-
gion of aggrecan in human articular cartilage. Biochem J 1996;
313(Pt 3):933e40.
93. Bayliss MT, Osborne D, Woodhouse S, Davidson C. Sulfation of chon-
droitin sulfate in human articular cartilage. The effect of age, topo-
graphical position, and zone of cartilage on tissue composition.
J Biol Chem 1999;274:15892e900.
94. Wells T, Davidson C, Morgelin M, Bird JL, Bayliss MT, Dudhia J. Age-
related changes in the composition, the molecular stoichiometry and
the stability of proteoglycan aggregates extracted from human articu-
lar cartilage. Biochem J 2003;370:69e79.
95. Grushko G, Schneiderman R, Maroudas A. Some biochemical and bio-
physical parameters for the study of the pathogenesis of osteoarthritis:
a comparison between the processes of ageing and degeneration in
human hip cartilage. Connect Tissue Res 1989;19:149e76.
96. Maroudas A, Bayliss MT, Uchitel-Kaushansky N, Schneiderman R,
Gilav E. Aggrecan turnover in human articular cartilage: use of as-
partic acid racemization as a marker of molecular age. Arch Biochem
Biophys 1998;350:61e71.
979Osteoarthritis and Cartilage Vol. 17, No. 897. Verzijl N, Bank RA, TeKoppele JM, DeGroot J. AGEing and osteoar-
thritis: a different perspective. Curr Opin Rheumatol 2003;15:616e22.
98. Verzijl N, DeGroot J, Thorpe SR, Bank RA, Shaw JN, Lyons TJ, et al.
Effect of collagen turnover on the accumulation of advanced glycation
endproducts. J Biol Chem 2000;275:39027e31.
99. DeGroot J, Verzijl N, Wenting-van Wijk MJ, Jacobs KM, Van El B, Van
Roermund PM, et al. Accumulation of advanced glycation end prod-
ucts as a molecular mechanism for aging as a risk factor in osteoar-
thritis. Arthritis Rheum 2004;50:1207e15.
100. Bank RA, Bayliss MT, Lafeber FP, Maroudas A, Tekoppele JM. Ageing
and zonal variation in post-translational modiﬁcation of collagen in
normal human articular cartilage. The age-related increase in non-en-
zymatic glycation affects biomechanical properties of cartilage. Bio-
chem J 1998;330(Pt 1):345e51.
101. Verzijl N, DeGroot J, Ben ZC, Brau-Benjamin O, Maroudas A,
Bank RA, et al. Crosslinking by advanced glycation end products in-
creases the stiffness of the collagen network in human articular carti-
lage: a possible mechanism through which age is a risk factor for
osteoarthritis. Arthritis Rheum 2002;46:114e23.
102. Chen AC, Temple MM, NgDM, Verzijl N, DeGroot J, TeKoppele JM, et al.
Induction of advanced glycation end products and alterations of the ten-
sile properties of articular cartilage. Arthritis Rheum 2002;46:3212e7.
103. DeGroot J, Verzijl N, Bank RA, Lafeber FP, Bijlsma JW,
TeKoppele JM. Age-related decrease in proteoglycan synthesis of hu-
man articular chondrocytes: the role of nonenzymatic glycation. Arthri-
tis Rheum 1999;42:1003e9.
104. Loeser RF, Yammani RR, Carlson CS, Chen H, Cole A, Im HJ, et al.
Articular chondrocytes express the receptor for advanced glycation
end products: Potential role in osteoarthritis. Arthritis Rheum 2005;
52:2376e85.
105. Steenvoorden MM, Huizinga TW, Verzijl N, Bank RA, Ronday HK,
Luning HA, et al. Activation of receptor for advanced glycation end
products in osteoarthritis leads to increased stimulation of chondro-
cytes and synoviocytes. Arthritis Rheum 2006;54:253e63.
106. Cecil DL, Johnson K, Rediske J, Lotz M, Schmidt AM, Terkeltaub R.
Inﬂammation-induced chondrocyte hypertrophy is driven by receptor
for advanced glycation end products. J Immunol 2005;175:8296e302.
107. Yammani RR, Carlson CS, Bresnick AR, Loeser RF. Increase in pro-
duction of matrix metalloproteinase 13 by human articular chondro-
cytes due to stimulation with S100A4: role of the receptor for
advanced glycation end products. Arthritis Rheum 2006;54:2901e11.
108. Wilkins E, Dieppe P, Maddison P, Evison G. Osteoarthritis and articular
chondrocalcinosis in the elderly. Ann Rheum Dis 1983;42:280e4.
109. Felson DT, Anderson JJ, Naimark A, Kannel W, Meenan RF. The prev-
alence of chondrocalcinosis in the elderly and its association with
knee osteoarthritis: the Framingham Study. J Rheumatol 1989;16:
1241e5.110. Rosenthal AK, Derfus BA, Henry LA. Transglutaminase activity in ag-
ing articular chondrocytes and articular cartilage vesicles. Arthritis
Rheum 1997;40:966e70.
111. Rosen F, McCabe G, Quach J, Solan J, Terkeltaub R, Seegmiller JE,
et al. Differential effects of aging on human chondrocyte responses
to transforming growth factor beta: increased pyrophosphate produc-
tion and decreased cell proliferation. Arthritis Rheum 1997;40:
1275e81.
112. Doherty M, Dieppe P. Clinical aspects of calcium pyrophosphate dihy-
drate crystal deposition. Rheum Dis Clin North Am 1988;14:395e414.
113. Pelletier JP, Martel-Pelletier J, Abramson SB. Osteoarthritis, an inﬂam-
matory disease: potential implication for the selection of new thera-
peutic targets. Arthritis Rheum 2001;44:1237e47.
114. Aigner T, Zien A, Gehrsitz A, Gebhard PM, McKenna L. Anabolic and
catabolic gene expression pattern analysis in normal versus osteoar-
thritic cartilage using complementary DNA-array technology. Arthritis
Rheum 2001;44:2777e89.
115. Goldring MB, Goldring SR. Osteoarthritis. J Cell Physiol 2007;213:
626e34.
116. Loeser RF. Molecular mechanisms of cartilage destruction: mechanics,
inﬂammatory mediators, and aging collide. Arthritis Rheum 2006;54:
1357e60.
117. Ferrucci L, Cavazzini C, Corsi A, Bartali B, Russo CR, Lauretani F,
et al. Biomarkers of frailty in older persons. J Endocrinol Invest
2002;25:10e5.
118. Andriacchi TP, Mundermann A, Smith RL, Alexander EJ, Dyrby CO,
Koo S. A framework for the in vivo pathomechanics of osteoarthritis
at the knee. Ann Biomed Eng 2004;32:447e57.
119. Lane NE, Bloch DA, Wood PD, Fries JF. Aging, long-distance running,
and the development of musculoskeletal disability. A controlled study.
Am J Med 1987;82:772e80.
120. Lane NE, Michel B, Bjorkengren A, Oehlert J, Shi H, Bloch DA, et al.
The risk of osteoarthritis with running and aging: a 5-year longitudinal
study. J Rheumatol 1993;20:461e8.
121. Sharma L, Song J, Felson DT, Cahue S, Shamiyeh E, Dunlop DD. The
role of knee alignment in disease progression and functional decline in
knee osteoarthritis. JAMA 2001;286:188e95.
122. Felson DT, Goggins J, Niu J, Zhang Y, Hunter DJ. The effect of body
weight on progression of knee osteoarthritis is dependent on align-
ment. Arthritis Rheum 2004;50:3904e9.
123. Roos H, Adalberth T, Dahlberg L, Lohmander LS. Osteoarthritis of the
knee after injury to the anterior cruciate ligament or meniscus: the in-
ﬂuence of time and age. Osteoarthritis Cartilage 1995;3:261e7.
124. Bukhari M, Lunt M, Barton A, Bunn D, Silman A, Symmons D. Increas-
ing age at symptom onset is associated with worse radiological dam-
age at presentation in patients with early inﬂammatory polyarthritis.
Ann Rheum Dis 2007;66:389e93.
